Last week Medibio, a company focused on how biometric markers impact mental health, launched a new app that integrates with the Apple Watch. The app works with the watch to collect biometrics, such as heart rate and then lets users see these markers in conjunction with their mental and overall health.
Every year, 3D printing offers more and more promise in the healthcare field. And while the ultimate goal of printing whole complex organs for transplants may still be decades away, 3D printing is helping to save and improve lives in ways - and in places - never imagined just a few years ago.
A technology that can change the way women check their baby’s health is in the final stages of development. PulseNmore LTD, an Israeli startup is developing a handheld ultrasound device that can be connected to any smartphone for monitoring the growth of a fetus.
With a view to widening the scope of treatment for ovarian cancer patients, EU regulators have greenlighted MSD’s Lynparza and stamped approval for a new dosing regimen and tablet formulation for AstraZeneca.
The American Heart Association, one of the leading non-profit organizations that foster cardiac care, is working to enhance community health through a new business line - Health Screening Services (HSS). The new health screening services will help consumers become more conscious of personal health risk factors and motivate them to make changes in their behaviors and lifestyle.
Based on data from the phase II JULIET study, tisagenlecleucel (Kymriah) has received FDA approval for the treatment of adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.
In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1) The Biologics License Application is supported by four Phase 3 studies of more than 2,000 patients with moderate to severe plaque psoriasis (1-3) Risankizumab is an investigational compound designed to selectively inhibit IL-23 by binding to its p19 subunit and is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing (4)
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.